KRAS and neoplasm: As a tumor suppressor, miR-193b has been reported to target cyclin D1 to regulate the cell cycle23, or directly inhibit oncogenes such as Mcl-1, c-KIT, MYB, and KRAS to attenuate tumorigenesis24–27.